Effects of Kinesio Tape on Delayed Onset Muscle Soreness
NCT ID: NCT04128670
Last Updated: 2025-11-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
36 participants
INTERVENTIONAL
2020-01-30
2026-05-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
During the first session (Baseline), the purpose and procedures of the research will be explained by the investigator, co-investigator, or a research assistant in more detail. Participants will read and sign the informed consent form and then undergo an exclusion/inclusion criteria assessment which includes the Physical Activity Readiness Questionnaire (PAR-Q), and brief questionnaire. All study personnel/staff obtaining informed consent will be trained in the responsible conduct of research. All participants will be asked if they have a known allergy to Kinesio Tape (KT) or if they have sensitive skin. Those with sensitive skin will be administered an allergy test. After screening and enrollment, participants will complete baseline assessments of muscle pain and function, pain sensitivity, and psychological risk factors (See outcome measures).
During Session 2, strength of the non-dominant bicep will be measured first. Participants will then perform an eccentric exercise protocol designed to induce delayed onset muscle soreness (DOMS) on the non-dominant arm. Strength of the non-dominant bicep will be measured immediately post the eccentric exercise protocol. At the end of this session, subjects will be randomly assigned to one of two intervention groups (experimental KT group, placebo KT group) or a control group (i.e., no intervention performed). The experimental group will receive KT with proper technique and tension (10-20%), while the placebo group will receive KT without technique and tension.
Sessions 3 and 4 will occur approximately 48 and 72 hours post Session 2, respectively. All the outcome variables will be measured during these sessions. For participants in the KT groups, the tape will be removed at the end of session 4, as described below.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Kinesiotape (KT)
Tape will be applied to the biceps muscle of the nondominant arm from approximately the shoulder to the elbow for up to 72 hours. For the KT group taping will be applied with a lymphatic application method according to the guidelines recommended by Kenzo Kase. This type of application is known to improve blood and lymphatic circulation which enhances the removal of metabolic products. The tape will be applied with a tension of 10-20%.
Kinesiotape
Tape will be applied to the biceps muscle of the nondominant arm from approximately the shoulder to the elbow for up to 72 hours. For the KT group taping will be applied with a lymphatic application method according to the guidelines recommended by Kenzo Kase. This type of application is known to improve blood and lymphatic circulation which enhances the removal of metabolic products. It is recommended that the application of the tape for lymphatic correction be applied for 24-72 hours. The tape will be applied with a tension of 10-20%.
Placebo Kinesiotape
Tape will be applied to the biceps muscle of the nondominant arm from approximately the shoulder to the elbow for up to 72 hours. The placebo KT group will have 0% tension.
Kinesiotape
Tape will be applied to the biceps muscle of the nondominant arm from approximately the shoulder to the elbow for up to 72 hours. For the KT group taping will be applied with a lymphatic application method according to the guidelines recommended by Kenzo Kase. This type of application is known to improve blood and lymphatic circulation which enhances the removal of metabolic products. It is recommended that the application of the tape for lymphatic correction be applied for 24-72 hours. The tape will be applied with a tension of 10-20%.
No Tape
This group will not receive any intervention.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Kinesiotape
Tape will be applied to the biceps muscle of the nondominant arm from approximately the shoulder to the elbow for up to 72 hours. For the KT group taping will be applied with a lymphatic application method according to the guidelines recommended by Kenzo Kase. This type of application is known to improve blood and lymphatic circulation which enhances the removal of metabolic products. It is recommended that the application of the tape for lymphatic correction be applied for 24-72 hours. The tape will be applied with a tension of 10-20%.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Regularly (\~2x per month) participating in strengthening exercises or activities that include lengthening actions of the upper extremity for the past 6 months.
* An answer of yes to any of the seven questions on the first page of the 2019 Physical Activity Readiness Questionnaire \[PAR-Q: 16\] indicating that the subject is not physically ready for exercise without a medical exam. These exclusions include the following:
* If participant's doctor has ever said that he/she has a heart condition or high blood pressure
* Pain in chest at rest, during daily activities of living, or when doing physical activity
* If participant has ever lost balance because of dizziness or has lost consciousness in the past 12 months
* If the participant currently has (or have had within the past 12 months) a bone, joint, or soft tissue (muscle, ligament, or tendon) problem that could be made worse by becoming more physically activity
* If participant is currently taking prescribed medications for a chronic medical condition
* If the participant's doctor has ever told them that they should only do medically supervised physical activity.
* Currently taking nutritional supplements or anti-inflammatory medication on a daily basis
* Any injury or surgery to the neck or upper extremity in the past 6 months
* Open or scabbed wounds in the arm area to be taped
* Known allergies to the tape or medical adhesive bandages
* If skin irritation develops to the tape
● Taking over-the-counter pain medications on days of testing, prior to testing sessions, including acetaminophen (Tylenol) and nonsteroidal inflammatory drugs (NSAIDs), including ibuprofen (Motrin, Advil) or naproxen (Aleve, Naprosyn).
18 Years
30 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Indiana University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kelly Naugle, PhD
Assistant Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Indiana University Purdue University Indianapolis
Indianapolis, Indiana, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Kelly M Naugle
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1908530527
Identifier Type: -
Identifier Source: org_study_id